Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (Zevalin) as Initial Therapy of Follicular Lymphoma
2006-000598-31Phase 2Completed
- Sponsor
- The Christie
- Start
- Sep 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by The Christie. Primary endpoints: Tumor response rate (CR, CRu, PR, ORR) and Safety. Started Sep 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2006-000598-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000598-31.